Mrna-Based Vaccines 30 µg and 100 µg Suppliers & Bulk Manufacturers
Available Forms: Injectable suspension
Available Strengths: 30 µg and 100 µg
Reference Brands: Comirnaty, Spikevax(US)
Category: Vaccines
mRNA vaccines work by delivering genetic instructions that enable cells to produce the coronavirus spike protein, triggering an immune response. They provide rapid, effective protection against COVID-19, reduce severe illness, support herd immunity, and are safe for most populations, supporting global vaccination efforts to control the pandemic.
Product Description:
mRNA-based vaccines, such as Pfizer-BioNTech’s Comirnaty and Moderna’s Spikevax, are approved in both the US and EU, supported by dossiers demonstrating safety, efficacy, and manufacturing quality in compliance with GMP and IVDR standards. In the US, FDA approval involves rigorous clinical trials, while in the EU, CE marking certifies conformity with in vitro diagnostic regulations. These vaccines undergo validation, stability testing, and quality audits, with comprehensive documentation including safety profiles, clinical trial data, and manufacturing processes. For licensing procedures, approved dossiers, and the latest regulatory updates, visit Pharmatradz. Ensuring regulatory compliance guarantees safe, effective COVID-19 protection globally, supporting public health efforts.
Mrna-Based Vaccines — third party manufacturing & bulk supply
Mrna-Based Vaccines 30 µg and 100 µg is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:
What to include when you enquire
- Destination market — determines which manufacturers hold the right site-level approvals
- First order quantity and estimated annual volume
- Whether you need a registration dossier or the product is already registered
- Packaging, labelling and language requirements
- Incoterms and required shelf life
Manufacturers of Mrna-Based Vaccines listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding. Narcotic drugs and controlled substances are supplied strictly against valid import and export permits issued by the competent authorities.
Request a quote for Mrna-Based Vaccines →The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Frequently Asked Questions
mRNA-based vaccines are used to prevent infectious diseases by stimulating the body’s immune system to produce a protective response against specific pathogens, such as viruses. The most well-known mRNA-based vaccines are those developed for COVID-19, which help the immune system recognize and fight the SARS-CoV-2 virus. These vaccines teach cells to produce a harmless piece of the virus (spike protein), triggering an immune response without using a live virus.
mRNA-based vaccines are made from messenger RNA (mRNA) that encodes the genetic instructions for cells to produce a viral protein. This mRNA is encapsulated within lipid nanoparticles that protect it and facilitate its delivery into human cells. Once inside the body, the mRNA instructs cells to make the target antigen, which then triggers an immune response.
Common trade names include Comirnaty (Pfizer-BioNTech COVID-19 Vaccine) and Spikevax (Moderna COVID-19 Vaccine).
The leading manufacturers of mRNA-based vaccines are Pfizer-BioNTech and Moderna. Other companies such as CureVac and Sanofi are also developing mRNA vaccine platforms for various infectious diseases and cancers.
There is no single generic name, as “mRNA-based vaccine” refers to a vaccine technology platform. For example, the generic name for Comirnaty is Tozinameran, and for Spikevax, it is Elasomeran.
Brand names include Comirnaty (Pfizer-BioNTech) and Spikevax (Moderna).
mRNA-based vaccines are manufactured by Pfizer-BioNTech in the USA and Germany, and by Moderna in the USA and Switzerland. Additional production and fill-finish facilities are located in Belgium, Spain, and other parts of Europe to meet global demand.
Related Products
Respiratory Syncytial Virus Mrna Vaccine
Strength:
0.5 mL
Form: injection (prefilled syringe)
Reference Brands: mRESVIA (USA/EU)
View Details
Inactivated Vaccines
Strength:
Dose and concentration depend on formulations
Form: Injectable suspension (IM administration), Lyophilized powder for reconstitution
Reference Brands: Sinovac Coronavac. Covaxin(EU)
View Details
Viral Vector Vaccines
Strength:
0.5 mL
Form: Intramuscular injectable suspension (IM)
Reference Brands: US: Johnson & Johnson’s Janssen (Jcovden)
View Details
Meningococcal Vaccine
Strength:
0.5 mL
Form: Vial or pre-filled syringe (injectable), Conjugate vaccines
Reference Brands: Menactra, Menveo(US), NmVac4-DT (India)
View DetailsQuick Response Guaranteed | Verified Suppliers
